Varenicline disrupts prepulse inhibition only in high-inhibitory rats

Simple item page
dc.contributor.authorGoktalay T.
dc.contributor.authorBuyukuysal S.
dc.contributor.authorUslu G.
dc.contributor.authorCoskun A.S.
dc.contributor.authorYorgancioglu A.
dc.contributor.authorKayir H.
dc.contributor.authorUzbay T.
dc.contributor.authorGoktalay G.
dc.date.accessioned2024-07-22T08:15:29Z
dc.date.available2024-07-22T08:15:29Z
dc.date.issued2014
dc.description.abstractVarenicline, a widely used smoking cessation drug, has partial agonistic activity at α4β2 nicotinic receptors, and full agonistic activity at α7 nicotinic receptors. Thus it may interact with cognitive processes and may alleviate some of the cognitive disturbances observed in psychotic illnesses such as schizophrenia. We aimed to test the effects of varenicline on sensorimotor gating functioning, which is crucial for normal cognitive processes, especially for the integration of sensory and cognitive information processing and the execution of appropriate motor responses. Prepulse inhibition (PPI) of the acoustic startle reflex was used to test the sensorimotor gating functioning. First, the effects of varenicline and nicotine on rats having high or low baseline PPI levels were evaluated; then, varenicline was applied prior to apomorphine (0.5. mg/kg), and MK-801 (0.15. mg/kg), which are used as comparative models of PPI disruption. Varenicline (0.5-3. mg/kg) did not change PPI when given alone in naïve animals. When rats were selected according to their baseline PPI values, varenicline (1. mg/kg) significantly decreased PPI in high-inhibitory (HI) but not in low-inhibitory (LI) rats. Nicotine (1. mg/kg; tartrate salt) produced a similar activity in LI and HI groups. In combination experiments, varenicline did not reverse either apomorphine or the MK-801-induced disruption of PPI. These results demonstrate that the effects of both varenicline and nicotine on sensorimotor gating are influenced by the baseline PPI levels. Moreover, varenicline has no effect on apomorphine or the MK-801-induced disruption of PPI. © 2014 Elsevier Inc.
dc.identifier.DOI-ID10.1016/j.pnpbp.2014.03.001
dc.identifier.issn02785846
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16736
dc.language.isoEnglish
dc.publisherElsevier Inc.
dc.subjectAcoustic Stimulation
dc.subjectAcoustics
dc.subjectAnalysis of Variance
dc.subjectAnimals
dc.subjectApomorphine
dc.subjectBenzazepines
dc.subjectDizocilpine Maleate
dc.subjectDopamine Agonists
dc.subjectDose-Response Relationship, Drug
dc.subjectExcitatory Amino Acid Antagonists
dc.subjectMale
dc.subjectNicotine
dc.subjectNicotinic Agonists
dc.subjectPrepulse Inhibition
dc.subjectQuinoxalines
dc.subjectRats
dc.subjectRats, Sprague-Dawley
dc.subjectReflex, Startle
dc.subjectapomorphine
dc.subjectdizocilpine
dc.subjectnicotine
dc.subjectvarenicline
dc.subjectamino acid receptor blocking agent
dc.subjectapomorphine
dc.subjectbenzazepine derivative
dc.subjectdizocilpine maleate
dc.subjectdopamine receptor stimulating agent
dc.subjectnicotine
dc.subjectnicotinic agent
dc.subjectquinoxaline derivative
dc.subjectvarenicline
dc.subjectanimal experiment
dc.subjectarticle
dc.subjectcontrolled study
dc.subjectdrug dose comparison
dc.subjectmale
dc.subjectmorning dosage
dc.subjectnonhuman
dc.subjectprepulse inhibition
dc.subjectrat
dc.subjectsensory gating
dc.subjectstartle reflex
dc.subjectacoustics
dc.subjectanalysis of variance
dc.subjectanimal
dc.subjectauditory stimulation
dc.subjectdose response
dc.subjectdrug effects
dc.subjectprepulse inhibition
dc.subjectSprague Dawley rat
dc.titleVarenicline disrupts prepulse inhibition only in high-inhibitory rats
dc.typeArticle

Files

Collections

Scopus Koleksiyonu